These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 2497954)

  • 41. [efficacy of the polysaccharide vaccine of Neisseria meningitidis group A].
    Yuan CD
    Zhonghua Liu Xing Bing Xue Za Zhi; 1983 Aug; 4(4):207-10. PubMed ID: 6416682
    [No Abstract]   [Full Text] [Related]  

  • 42. Is there a genetic immune defect in families with meningococcal meningitis?
    Whittle HC; Werblinska J; Hassan-King M; Greenwood BM; Wolf E; Festenstein H; van Loghem E
    J Infect; 1981 Jun; 3(2):140-9. PubMed ID: 6821093
    [No Abstract]   [Full Text] [Related]  

  • 43. Pathogenic neisseriae: surface modulation, pathogenesis and infection control.
    Virji M
    Nat Rev Microbiol; 2009 Apr; 7(4):274-86. PubMed ID: 19287450
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vaccine against meningococcal group B disease.
    Lifely MR; Moreno C
    Lancet; 1986 Jan; 1(8474):214-5. PubMed ID: 2868239
    [No Abstract]   [Full Text] [Related]  

  • 45. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency.
    Ross SC; Densen P
    Medicine (Baltimore); 1984 Sep; 63(5):243-73. PubMed ID: 6433145
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

  • 47. [Report of the 3d International Conference on the immunology of meningococcal meningitis. Current status of meningococcus B vaccine].
    Del Real G
    Rev Sanid Hig Publica (Madr); 1979; 53(11-12):1639-49. PubMed ID: 45419
    [No Abstract]   [Full Text] [Related]  

  • 48. In vitro inhibition of growth of Neisseria gonorrhoeae by Neisseria meningitidis isolated from the pharynx of homosexual men.
    Bisaillon JG; Turgeon P; Dubreuil D; Beaudet R; Sylvestre M; Ashton FE
    Sex Transm Dis; 1984; 11(4):296-300. PubMed ID: 6441274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dynamics of bacterial carriage and disease: lessons from the meningococcus.
    Maiden MC
    Adv Exp Med Biol; 2004; 549():23-9. PubMed ID: 15250512
    [No Abstract]   [Full Text] [Related]  

  • 50. Factors influencing host susceptibility to meningococcal disease.
    Winstanley FP; Blackwell CC; Weir DM
    Biomed Pharmacother; 1985; 39(4):167-70. PubMed ID: 3933588
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Vaccines against Neisseria meningitidis].
    Ferrón L; Criado MT; Ferreirós CM
    Enferm Infecc Microbiol Clin; 1992 May; 10(5):296-301. PubMed ID: 1391002
    [No Abstract]   [Full Text] [Related]  

  • 52. Relationship of dose to the reactogenicity and immunogenicity of meningococcal polysaccharide vaccines in adults.
    Griffiss JM; Brandt BL; Broud DD; Altieri PL; Berman SL
    Mil Med; 1985 Oct; 150(10):529-33. PubMed ID: 3934585
    [No Abstract]   [Full Text] [Related]  

  • 53. [Preventive effectiveness of an urgent mass vaccination with purified meningococcal polysaccharide vaccine observed during a meningitis epidemic].
    Wu C
    Zhonghua Liu Xing Bing Xue Za Zhi; 1985 Dec; 6(6):344-6. PubMed ID: 3938683
    [No Abstract]   [Full Text] [Related]  

  • 54. [Immune response to meningococci].
    Flaegstad T
    Tidsskr Nor Laegeforen; 1989 Jan; 109(1):33-6. PubMed ID: 2492123
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neisseria gonorrhoeae vaccine development: hope on the horizon?
    Edwards JL; Jennings MP; Seib KL
    Curr Opin Infect Dis; 2018 Jun; 31(3):246-250. PubMed ID: 29601324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease.
    Fischer M; Carlone GM; Holst J; Williams D; Stephens DS; Perkins BA
    Vaccine; 1999 May; 17(19):2377-83. PubMed ID: 10392619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Measurement of growth-inhibiting (bactericidal) antibodies in patients with meningococcal meningitis and in subjects immunized with meningococcal polysaccharide vaccine by a [3H]thymidine assay.
    Hassan-King M; Greenwood BM; Whittle HC
    J Clin Microbiol; 1985 Jul; 22(1):136-8. PubMed ID: 3926814
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Another Swedish family with complete properdin deficiency: association with fulminant meningococcal disease in one male family member.
    Söderström C; Sjöholm AG; Svensson R; Ostenson S
    Scand J Infect Dis; 1989; 21(3):259-65. PubMed ID: 2502833
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccine for meningococcal meningitis tested.
    Marwick C
    JAMA; 1991 Oct; 266(15):2052-3. PubMed ID: 1920685
    [No Abstract]   [Full Text] [Related]  

  • 60. Evidence of serum antibodies to Neisseria gonorrhoeae before gonococcal infection.
    Hicks CB; Boslego JW; Brandt B
    J Infect Dis; 1987 Jun; 155(6):1276-81. PubMed ID: 2883240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.